The efficacy and safety of anti-interleukin-6 receptor monoclonal blockade in a renal transplant patient with Castleman disease: early post-transplant outcome
- 401 Downloads
Multicentric Castleman disease (MCD) is an uncommon lymphoproliferative disease characterized by systemic inflammatory reactions associated with the dysregulated production of interleukin-6 (IL-6). In patients with MCD, renal involvement is uncommon, with only one report published regarding kidney transplantation (KTx) to treat end-stage renal disease (ESRD) secondary to MCD. Recent clinical observations have shown that IL-6 production is implicated in allograft rejection, while IL-6 receptor blockade (with tocilizumab [TCZ]) reduces alloantibody generation and thereby improves graft survival; however, the efficacy and safety of TCZ in MCD patients undergoing KTx is still unknown.
Herein, we describe the case of a 50-year-old man with MCD who received living-donor KTx for ESRD. Post-operative immunosuppression consisted of a triple-drug regimen (tacrolimus, mycophenolate mofetil and methylprednisolone) with TCZ that was administered intravenously every 2 weeks. At 17 months post-transplantation, the patient remains asymptomatic, and the allograft pathology has shown no evidence of rejection and no development of de novo donor-specific antibody (DSA).
To our knowledge, this is the second reported case of an MCD patient with ESRD who underwent successful KTx. TCZ safely supported the patient during the perioperative period, and this drug may be useful for blocking the generation of donor-specific antibodies and reducing the risk of rejection episodes. KTx in combination with TCZ is thus considered a viable treatment option for ESRD due to MCD.
KeywordsCastleman disease Kidney transplantation Tocilizumab IL-6 IgA nephropathy
End-stage renal disease
Multicentric Castleman disease
Castleman disease (CD) is an uncommon heterogeneous group of lymphoproliferative disorders with three histological types (hyaline vascular type, plasma cell type, and mixed type). CD can occur in a localized (unicentric CD: UCD) or widespread (multicentric CD: MCD) form. The aetiology of CD is not well understood; however, excessive production of interleukin 6 (IL-6) by lymph node hyperplasia has been implicated in its pathogenesis [1, 2, 3]. The clinical features include generalized lymphadenopathy, organomegaly, and systemic manifestations, such as fatigue, a low-grade fever, and weight loss. Abnormal laboratory findings include anaemia, hypoalbuminaemia, hypocholesterolaemia, hypergammaglobulinaemia, and increased levels of C-reactive protein (CRP) [1, 2, 3]. Renal involvement in MCD seems to be uncommon and has been described in only a few case series [4, 5]. To date, there has been only one report of kidney transplantation (KTx) for the treatment of end-stage renal disease (ESRD) secondary to MCD .
IL-6 is a key cytokine that impacts the development and maturation of T cells, B cells, and antibody producing plasma cells. Excessive IL-6 production has been linked to several human diseases characterized by unregulated antibody production and autoimmunity, such as CD [1, 2]. Tocilizumab (TCZ; Actemra®, Roche/Genentech, San Francisco, CA, USA) is a first-in-class humanized monoclonal blockade targeting the IL-6 receptor (IL-6R). TCZ binds to both soluble and membrane-bound forms of the IL-6R and is approved for the treatment of CD [1, 2].
A recent study of TCZ for patients undergoing KTx showed a significant reduction in donor-specific antibody (DSA) production and improvement in the transplantation graft survival [7, 8]. IL-6R interactions have been shown to be critical for alloantibody generation in an animal model of alloimmunity. IL-6 modulates T cell immunity and is a powerful stimulant of pathogenic IgG production, so the blockade of these interactions with an anti–IL-6R monoclonal blockade results in significant reductions in alloantibodies [7, 8]. However, the efficacy and safety of TCZ in MCD patients undergoing KTx is still unknown. To answer this question, we herein report the second known case of an MCD patient with ESRD who successfully underwent living-donor KTx using TCZ.
A 33-year-old man visited an outpatient clinic with haematuria and proteinuria. One year later, the patient was diagnosed with IgA nephropathy by a renal biopsy and was treated with diet and medication. At 36 years of age, his began to experience fatigue and weight loss. He was had generalized lymphadenopathy, hepatosplenomegaly, and elevated CRP levels, and his IL-6 level had gradually increased. Chest CT revealed slight enlargement of the mediastinal lymph nodes, centrilobular nodules, thickening of the bronchovascular bundles, and ground-glass opacities. These clinical findings were consistent with MCD. Hepatitis B, hepatitis C, syphilis, and HIV screening were negative. His renal function gradually declined over the following decade, resulting in ESRD. At 44 years of age, peritoneal dialysis was started for the treatment of ESRD, and an inguinal lymph node biopsy was performed to confirm the diagnosis, revealing the typical features of plasma cell-type MCD. Oral prednisolone (PSL) (10 mg/day) was initially administered; however, none of his clinical or laboratory parameters were fully resolved.
The patient’s IL-6 levels decreased dramatically after transplantation and are now maintained at 300–500 pg/ml under immunosuppression with a triple-drug regimen (TAC, MMF and mPSL) with TCZ (Fig. 2). In addition, the patient experienced increases in albumin, haemoglobin and haematocrit (data not shown), along with normalized CRP and IgG (Fig. 2).
On post-operative days 20 and 238, a transplant renal biopsy was performed and showed no rejection or virus infection. To evaluate for the presence of anti-HLA antibodies, a single-antigen bead assay (LABScreen Single Antigen) was performed. DSA was negative both before transplantation and on post-operative day 239.
At present, 17 months after KTx, the patient remains asymptomatic, and the allograft function has been preserved without evidence of rejection. In addition, haematologic follow-up has not demonstrated any significant adverse effects of TCZ (such as dyslipidaemia or myelosuppression) or cytomegalovirus (CMV) infection events.
Discussion and conclusions
This case highlights two important clinical implications: MCD with ESRD can be successfully treated by KTx, and TCZ is useful for MCD and ensures a safe perioperative period during KTx.
In the past, the treatment of CD has included various therapeutic strategies, such as steroids, rituximab, and chemotherapy. However, since there is no standard therapy, treatment recommendations for CD can be difficult . Recently, TCZ was shown to be effective for treatment and has been widely used in Japan since June 2005 [1, 2, 9, 10].
While renal involvement associated with MCD is rare, its manifestations can vary and include minimal disease changes, mesangial proliferative glomerulonephritis, AA amyloidosis, thrombotic microangiopathy (TMA) and IgA nephropathy [4, 5, 11, 12, 13, 14]. In particular, IgA nephropathy associated with MCD is quite rare . In our patient, in addition to the diagnosis of IgA nephropathy, numerous IgA-positive cells were detected in the lymph node and lung specimens. This result is consistent with those of a recent study, which found that the detection of increased immunohistochemical IgA expression can be useful for diagnosing CD . Furthermore, ESRD as a complication of MCD has rarely been reported, and to our knowledge, only one report has described successful KTx for an MCD patient . Murakami et al. reported an MCD patient with ESRD who underwent KTx. The patient developed acute rejection soon after KTx but was successfully treated with a steroid pulse, plasmapheresis, anti-CD3 and rituximab. The graft survival was 8 years, and the graft function remained excellent.
In patients with CD, increased IL-6 and CRP levels have been noted [1, 2, 12, 13, 14]. CD exacerbation is correlated with the levels of both IL-6 and CRP; IL-6 induces the synthesis of hepatic acute-phase reactants and increases CRP and IgG levels. In our patient, his IL-6 levels decreased dramatically after transplantation with induction therapy from 3480 pg/ml to 341 pg/ml. We suspect that induction therapy might have dramatically decreased his IL-6 levels.
IL-6 is a major cytokine involved in the progression of B cells to IgG-secreting plasmablasts and finally to plasma cells. In addition, IL-6 stimulates Th17 cells, which mediate inflammation and allograft rejection. Recent studies have suggested that TCZ can inhibit antibody production and reduce inflammation by targeting the IL-6/IL-6R pathway [16, 17, 18]. Jordan et al. reported on the efficacy of TCZ in reducing anti-HLA antibodies and improving the graft survival in highly HLA-sensitized patients who were resistant to other desensitization strategies. Furthermore, they offered TCZ treatment to chronic antibody-mediated rejection patients in whom other treatment options had failed, and significant reductions in DSA and stabilization of renal function were seen at 2 years [7, 8].
Another study suggested that TCZ may be useful for preventing post-transplant graft-versus-host disease (GVHD) . Kennedy et al. reported that the addition of TCZ to the standard GVHD prophylaxis for patients who had received allogenic stem-cell transplantation was safe and associated with a very low incidence of GVHD.
The long-term use of TCZ is optimal for the treatment of MCD; thus, treatment with TCZ may allow KTx patients to reduce or discontinue their conventional immunosuppression and mitigate related side effects, such as hypertension, dyslipidaemia, de novo diabetes, infection, and malignancies . We therefore expect immunosuppression after KTx to also be effective for MCD.
In summary, we suggested a treatment protocol for renal replacement therapy using TCZ for MCD patients with ESRD. While the IL-6R monoclonal antibody TCZ was shown to be effective for treating MCD, it may also be used to reduce the risk of chronic antibody-mediated rejection and thereby possibly improve long-term graft survival [7, 8]. Although the indications for elective KTx in MCD patients remain limited, continued success and reports of good outcomes may help establish KTx as an acceptable therapeutic option.
The author would like to thank Dr. Hiroshi Harada and Dr. Hisako Saito for their careful patient management at Showa University Fujigaoka Hospital in Yokohama, Japan.
Availability of data and materials
All the data supporting our findings is contained within the manuscript.
MM designed and wrote the manuscript. KS, YO, MO, Kazuya Kinoshita, KT and YN treated the patient. Keiichi Kinowaki, KO, TF, TI and YS supplied the pathology reports. YU and YI supervised the transplant program and corrected the manuscript. All authors read and approved the final manuscript.
Ethics approval and consent to participate
Consent for publication
Written informed consent was obtained from the patient to publish this case report and any accompanying images. A copy of the written consent is available for review by the editor of this journal.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
- 2.Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood. 2008;112(10):3959–64.CrossRefGoogle Scholar
- 8.Choi J, Aubert O, Vo A, Loupy A, Haas M, Puliyanda D, Kim I, Louie S, Kang A, Peng A, et al. Assessment of tocilizumab (anti-Interleukin-6 receptor monoclonal) as a potential treatment for chronic antibody-mediated rejection and transplant Glomerulopathy in HLA-sensitized renal allograft recipients. Am J Transplant. 2017;17(9):2381–9.CrossRefGoogle Scholar
- 9.Oshima Y, Hoshino J, Suwabe T, Hayami N, Yamanouchi M, Sekine A, Ueno T, Mizuno H, Yabuuchi J, Imafuku A, et al. Multicentric Castleman's disease associated with IgA vasculitis (Henoch-Schonlein purpura) responding well to tocilizumab: a case report. Clin Rheumatol. 2017;36(3):729–33.CrossRefGoogle Scholar
- 13.Ogita M, Hoshino J, Sogawa Y, Sawa N, Katori H, Takemoto F, Ubara Y, Hara S, Miyakoshi S, Takaichi K. Multicentric Castleman disease with secondary AA renal amyloidosis, nephrotic syndrome and chronic renal failure, remission after high-dose melphalan and autologous stem cell transplantation. Clin Nephrol. 2007;68(3):171–6.CrossRefGoogle Scholar
- 17.Vo AA, Choi J, Kim I, Louie S, Cisneros K, Kahwaji J, Toyoda M, Ge S, Haas M, Puliyanda D, et al. A phase I/II trial of the Interleukin-6 receptor-specific humanized monoclonal (tocilizumab) + intravenous immunoglobulin in difficult to desensitize patients. Transplantation. 2015;99(11):2356–63.CrossRefGoogle Scholar
- 19.Kennedy GA, Varelias A, Vuckovic S, Le Texier L, Gartlan KH, Zhang P, Thomas G, Anderson L, Boyle G, Cloonan N, et al. Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1/2 trial. Lancet Oncol. 2014;15(13):1451–9.CrossRefGoogle Scholar
- 20.Madariaga ML, Spencer PJ, Shanmugarajah K, Crisalli KA, Chang DC, Markmann JF, Elias N, Cosimi AB, Sachs DH, Kawai T. Effect of tolerance versus chronic immunosuppression protocols on the quality of life of kidney transplant recipients. JCI Insight 2016;1(8).Google Scholar
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.